NCT05394493View on ClinicalTrials.gov

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

avelumab

as provided in real world setting

DRUG

axitinib

as provided in real world settings

Trial Locations (1)

CT13 9NJ

Pfizer Ltd, Sandwich

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05394493 - An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK | Biotech Hunter | Biotech Hunter